drugset / Trial / NCT00648063
Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
RandomizedCrossoverOpen-label
Summary
The objective of this study was to investigate the bioequivalence of Mylan's letrozole 2.5 mg tablets to Novartis' Femara® 2.5 mg tablets following a single, oral 2.5 mg (1 x 2.5 mg) dose administered under fasting conditions.
Timeline
- Start
- 2005-11
- Primary completion
- 2005-12
- Completion
- 2006-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
Indications
No indication recorded.